[A25-04] AR101 (peanut allergy, 1 to 3 years) – Benefit assessment according to §35a Social Code Book V
Last updated 15.04.2025
Project no.:
A25-04
Commission:
Commission awarded on 15.01.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Children aged 1 to 3 years with a confirmed diagnosis of peanut allergy
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-04
| Project no. | Title | Status |
|---|---|---|
| A21-135 | AR101 (Peanut allergy) - Benefit assessment according to §35a Social Code Book V | Commission completed |